Sierra Oncology Receivables

Sierra Oncology (SRRA) currently reports a receivables of $270K as of March 2022. That compares with $210K in the prior-year period — up 26.2% year over year. Use the charts on this page to explore Sierra Oncology's receivables history and peer comparisons.

Sierra Oncology's receivables increased from $210K to $270K — a 26.2% year-over-year increase (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sierra Oncology reported $270K in receivables as of March 2022. That compares with $210K in the prior-year period — up 26.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $270K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sierra Oncology, and consider following SRRA for alerts when major investors trade the stock.

Sierra Oncology is classified in the Healthcare sector. On receivables, it currently shows $270K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SRRA with unrelated industries.